genomics-integrative-biology-2018-posters

23 / 31

Page 107
conferenceseries.com
Volume 12 Journal of Molecular and Genetic Medicine
ISSN: 1747-0862
May 21-23, 2018 Barcelona, Spain
&
Integrative Biology
6th International Conference on
Genomics and Molecular Biology
10th International Conference on
Genomics 2018 and Integrative Biology 2018
May 21-23, 2018
JOINT EVENT
Regulation of aberrant inflammatory responses and development of vascular disease through the IL-
1RI co-receptor TILRR
Eva E Qwarnstrom
University of Sheffield, UK
Members of the toll-like and IL-1 receptor family (TIR) are central regulators of immune and inflammatoryresponses.
Signal activation is induced through ligand binding and controlled by system-specific have identified
a novel component of the IL-1receptor complex,the co-receptor TILRR (FREM-1isoform 2). TILRR associates with the
signallingreceptor and magnifies IL-1induced activation of the transcription factor NF-κB by enhancing signalamplification
at the level of the receptor complex and potentiate recruitment of the MyD88 adapter.TILRR-controlled MyD88 dependent
activation is regulated in a Ras-dependent manner, reflected inalterations in cytoskeletal structure and cell adhesion, and
in release of cytoskeletal bound IκBα. In silicosimulations using agent based modeling of the NF-κB network predicts the
cytoskeletal control of inhibitorlevels provides a mechanism for rapid signal calibration, and enables activation-sensitive
regulation of NF-κBinducedinflammatory responses.Recent studies have used in vivo models to assess the role of TILRR in
host defense, vascular diseaseand lung fibrosis. Results show that TILRR expression is increased in inflammatory cells during
developmentof myocardial infarction and in areas of inflammation, such as the atherosclerotic plaque and lymphoid tissuein
the lung, but present at low levels in healthy tissue. Further, they demonstrate that genetic deletion orantibody blocking of
TILRR function reduces development of disease progression, and suggest that TILRRprovides a novel rational target for site-
and signal specific inhibition of inflammatory responses in disease.
J Mol Genet Med 2018, Volume 12
DOI: 10.4172/1747-0862-C2-028